welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Avidity Biosciences Receives Investment from CureDuchenne
Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
rareRelated
-
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease P...PTC Therapeutics, Inc. today announced p...
-
Becker Muscular Dystrophy – A Natural History Study to Predict Efficacy of Exon SkippingThis is a multi-center natural history s...
-
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
-
Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophinEvox Therapeutics Ltd, a leading exosome...
-
Single CRISPR Treatment Provides Long-Term Benefits in MiceResearchers at Duke University have show...
-
Santhera Provides Update on Filing for Conditional Marketing Authorization in Europe for Puldysa® (Idebenone) in Du...Santhera Pharmaceuticals announces its i...
-
Statement from FDA Commissioner Scott Gottlieb, M.D. on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are n...